Literature DB >> 31362308

Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.

Jacob T Kilgore1, Bradford Becken1, Matthew G Varga2, Suhag Parikh3, Vinod Prasad3, Debra Lugo1,4, Yeh-Chung Chang1,4.   

Abstract

We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.
© The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antiviral resistance; cytomegalovirus (CMV); hematopoietic stem cell transplant; letermovir

Mesh：

Substances：

Year:  2020        PMID： 31362308      PMCID： PMC7495908          DOI： 10.1093/jpids/piz050

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  10 in total

Review 1.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

2.  The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors:  Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  P Ljungman; G L Deliliers; U Platzbecker; S Matthes-Martin; A Bacigalupo; H Einsele; J Ullmann; M Musso; R Trenschel; P Ribaud; M Bornhäuser; S Cesaro; B Crooks; A Dekker; N Gratecos; T Klingebiel; E Tagliaferri; A J Ullmann; P Wacker; C Cordonnier
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

Review 4.  Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.

Authors:  Kaiwen Chen; Matthew P Cheng; Sarah P Hammond; Hermann Einsele; Francisco M Marty
Journal:  Blood Adv       Date:  2018-08-28

5.  Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.

Authors:  J F Manischewitz; G V Quinnan; H C Lane; A E Wittek
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

7.  Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

8.  Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.

Authors:  T Bontant; P Sedlaçek; A Balduzzi; B Gaspar; S Cesaro; H Einsele; C Peters; J-H Dalle
Journal:  Bone Marrow Transplant       Date:  2013-10-28       Impact factor: 5.483

Review 9.  Cytomegalovirus Treatment.

Authors:  Ban Hock Tan
Journal:  Curr Treat Options Infect Dis       Date:  2014

Review 10.  Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Justyna Ogonek; Mateja Kralj Juric; Sakhila Ghimire; Pavankumar Reddy Varanasi; Ernst Holler; Hildegard Greinix; Eva Weissinger
Journal:  Front Immunol       Date:  2016-11-17       Impact factor: 7.561
  10 in total
  3 in total

Review 1.  Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.

Authors:  Morgan Hakki
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 4.213

2.  Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant.

Authors:  Angela Chiereghin; Tamara Belotti; Eva Caterina Borgatti; Nicola Fraccascia; Giulia Piccirilli; Maura Fois; Michele Borghi; Gabriele Turello; Liliana Gabrielli; Riccardo Masetti; Arcangelo Prete; Stefano Fanti; Tiziana Lazzarotto
Journal:  Infect Drug Resist       Date:  2021-03-23       Impact factor: 4.003

Review 3.  Cytomegalovirus in Haematological Tumours.

Authors:  Sara Alonso-Álvarez; Enrique Colado; Marco A Moro-García; Rebeca Alonso-Arias
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.